A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 35/00 (2006.01) A61K 48/00 (2006.01) C07H 21/04 (2006.01) C12N 15/63 (2006.01) C12N 15/861 (2006.01)
Patent
CA 2291262
A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered directly or systemically (intravascularly) to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.
Un agent thérapeutique basé sur un adénovirus recombinant, qui utilise un promoteur de l'ostéocalcine pour l'expression de la thymidine kinase, peut être administré directement ou par voie systémique (intravasculaire) pour traiter les cancers métastatiques, notamment l'ostéosarcome, le cancer du sein, le cancer de la prostate, le mélanome oculaire et le cancer du cerveau. L'administration systémique de cet agent est une voie préférée par rapport à l'administration locale directe. Le même agent thérapeutique peut être utilisé de manière efficace pour traiter des pathologies bénignes, notamment l'hypertrophie bénigne de la prostate et l'artériosclérose.
Cheon Jun
Chung Leland W.k.
Kao Chinghai
Ko Song-Chu
Sikes Robert A.
Osler Hoskin & Harcourt Llp
University Of Virginia Patent Foundation
LandOfFree
Osteocalcin promoter-based toxic gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Osteocalcin promoter-based toxic gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osteocalcin promoter-based toxic gene therapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2061693